Patents by Inventor Michael V. Milburn
Michael V. Milburn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220034865Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.Type: ApplicationFiled: June 11, 2021Publication date: February 3, 2022Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
-
Publication number: 20200110069Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.Type: ApplicationFiled: October 14, 2019Publication date: April 9, 2020Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
-
Publication number: 20200025729Abstract: Methods and systems are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: ApplicationFiled: February 26, 2019Publication date: January 23, 2020Applicant: Metabolon, Inc.Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Patent number: 10502729Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.Type: GrantFiled: February 4, 2016Date of Patent: December 10, 2019Assignee: Metabolon, Inc.Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
-
Patent number: 10267777Abstract: Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: GrantFiled: October 7, 2016Date of Patent: April 23, 2019Assignee: Metabolon, Inc.Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Publication number: 20180314790Abstract: Methods using a combination of metabolomics and computer technology to determine sequence variants with potential negative or detrimental effects and enable the classification of a variant with an unknown or uncertain clinical significance from VUS status to benign, pathogenic or advantageous are described. For example, methods of using metabolomics to expedite personalized medicine based on genomic sequence analysis are described. Using metabolic profiles to determine (or aid in determining) the significance of genetic variants and enable the identification of diagnostic variants (those variants having a detrimental health affect) for use in personalized medicine is described. Further, using metabolic profiles to determine the presence of advantageous variants that may have a positive effect on patient health is also described.Type: ApplicationFiled: November 4, 2015Publication date: November 1, 2018Inventors: Shaun Lonergan, John A. Ryals, Michael V Milburn, Adam Kennedy, Lining Guo, Kay A Lawton
-
Publication number: 20180031541Abstract: The present invention provides a method for diagnosing a disease or disorder selected from the group consisting of insulin resistance, a metabolic disorder, diabetes and pre-diabetes in a subject. The method comprises the step of determining the level of a compound represented by structural formula (VI): or a salt thereof. Compositions and method of making thereof are also described.Type: ApplicationFiled: February 4, 2016Publication date: February 1, 2018Inventors: Luke Miller, Klaus Peter Adam, Michael V. Milburn, Jeffery E. Cobb, Anne M. Evans, Qibo Zhang
-
Publication number: 20170089872Abstract: Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.Type: ApplicationFiled: October 7, 2016Publication date: March 30, 2017Inventors: Michael V. Milburn, John A. Ryals, Lining Guo, Andrea Eckhart, Jacob Wulff, Adam D. Kennedy, Thomas J. Jönsson, Ryan Douglas Michalek, Bryan Wittmann, Matthew Mitchell
-
Publication number: 20140303228Abstract: The disclosure provides biomarkers of amyotrophic lateral sclerosis (ALS). The disclosure also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.Type: ApplicationFiled: October 17, 2012Publication date: October 9, 2014Inventors: Kay A. Lawton, Meredith V. Brown, Bruce Neri, Rebecca Caffrey, Michael V. Milburn
-
Patent number: 8849577Abstract: Methods for metabolomically determining the biological affects of compounds are described.Type: GrantFiled: September 17, 2007Date of Patent: September 30, 2014Assignee: Metabolon, Inc.Inventors: John A. Ryals, Daniel P. Stevens, Michael V. Milburn
-
Patent number: 8367828Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.Type: GrantFiled: April 28, 2010Date of Patent: February 5, 2013Assignee: Plexxikon Inc.Inventors: James Arnold, Dean R. Artis, Clarence R. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
-
Publication number: 20100210036Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.Type: ApplicationFiled: April 28, 2010Publication date: August 19, 2010Inventors: James Arnold, Dean R. Artis, Clarence H. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
-
Patent number: 7572806Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.Type: GrantFiled: December 7, 2007Date of Patent: August 11, 2009Assignee: Plexxikon, Inc.Inventors: James Arnold, Dean R. Artis, Clarence R. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
-
Publication number: 20080161228Abstract: Methods for metabolomically determining the biological affects of compounds are described.Type: ApplicationFiled: September 17, 2007Publication date: July 3, 2008Applicant: Metabolon Inc.Inventors: John A. Ryals, Daniel P. Stevens, Michael V. Milburn
-
Patent number: 7348338Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.Type: GrantFiled: September 8, 2004Date of Patent: March 25, 2008Assignee: Plexxikon, Inc.Inventors: James Arnold, Dean R. Artis, Clarence R. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
-
Patent number: 7202266Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.Type: GrantFiled: July 16, 2004Date of Patent: April 10, 2007Assignee: Plexxikon, Inc.Inventors: James Arnold, Dean R. Artis, Clarence R. Hurt, Prabha N. Ibrahim, Heike Krupka, Jack Lin, Michael V. Milburn, Weiru Wang, Chao Zhang
-
Publication number: 20040142864Abstract: A crystal structure of PIM-1 is described that was determined by X-ray crystallography. The use of PIM-1 crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate PIM-1 and other PIM kinases.Type: ApplicationFiled: September 16, 2003Publication date: July 22, 2004Applicant: Plexxikon, Inc.Inventors: Ryan Bremer, Prabha Ibrahim, Abhinav Kumar, Valsan Mandiyan, Michael V. Milburn